CDC Health Advisory: Updated Information on Availability and Use of Treatments for Outpatients with Mild to Moderate COVID-19 Who are at Increased Risk for Severe Outcomes of COVID-19

Date:4/25/2022
Official Message No.:111305-4-25-2022-PHAD
Contact Info: Kim | Kim.Cervantes@doh.nj.gov
Attachments: Yes Attachment 1

Please see the attached Centers for Disease Control and Prevention (CDC) Health Advisory: Updated Information on Availability and Use of Treatments for Outpatients with Mild to Moderate COVID-19 Who are at Increased Risk for Severe Outcomes of COVID-19.

CDC is issuing this Advisory to update healthcare providers, public health departments, and the public about the availability and use of recommended therapies for COVID-19 and to advise against using unproven treatments that have known or potential harms for outpatients with mild to moderate COVID-19. For patients with mild to moderate COVID-19 who are not hospitalized and who are at increased risk for severe COVID-19 outcomes, several treatment options, including antiviral medications and monoclonal antibodies, are now widely available and accessible.

Healthcare providers can find additional information on COVID-19 therapeutics in New Jersey online at the COVID-19 Information HUB or through the COVID-19 Therapeutics Operations Center at COVID.Pharma@doh.nj.gov or (609)-913-5800.


This information has been broadcast to: Community Health Centers (FQHCs); Long-term Care; Health Care Facilities / Other; Health Care Organizations; Health Care Providers; Hospital Staff Directory; Hospital CEOs; Hospital Emerg Preparedness Coords; Hospital ER Medical Directors; Hospital Infection Control Practitioners; Hospital Medical Directors; Hospital Nursing Directors; Hospital Security Directors; ICU Administrator; Lab Director; Hospitals / Acute Care; Hospitals / Other; Hospitals / Veterans; Pharmaceutical Suppliers; Local Boards of Health; NJDOH Staff; NJLINCS and Local Contacts; NJLINCS Community; Public Health Associations; Public Health Council; Public Health Sector